Clinical Trials
320 trialsAtezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Universitair Ziekenhuis Brussel
Elacestrant in Advanced Triple Positive Breast Cancer
NYU Langone Health
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
University of Washington
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
University of Illinois at Chicago
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
JAZMINE
MedSIR
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
Memorial Sloan Kettering Cancer Center
PIKHER2
Institut Paoli-Calmettes
TAKTIC
Institut Paoli-Calmettes
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
Cedars-Sinai Medical Center
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Washington University School of Medicine
Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors
University of Miami
ART
Weill Medical College of Cornell University
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Nagoya City University
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Georgetown University
ERADICATE
Dana-Farber Cancer Institute
HER2-PET Imaging in HER2-low Breast Cancers
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Weill Medical College of Cornell University
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Icahn School of Medicine at Mount Sinai
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Massachusetts General Hospital
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
BreastVAX
Abramson Cancer Center at Penn Medicine
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
University of Virginia
Breast-47
University of Virginia
HeartPhone Cancer Survivors Trial 2019
Penn State University
SELECT-CAR-NK
Essen Biotech
EBNK-ST-001
Essen Biotech
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
University of Florida
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
Baylor College of Medicine
NoCUT-BC
Ohio State University Comprehensive Cancer Center
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Onvansertib + Paclitaxel In TNBC
Dana-Farber Cancer Institute
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
Tanta University
ADRIAN
University of Maryland, Baltimore
Target-specific immunoPET Imaging of Breast Cancer
RenJi Hospital
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
University of Alabama at Birmingham
TAGNOT
Kidney Cancer Research Bureau
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
Néo-APBI-01
University Hospital, Grenoble
SOLARA
Hoosier Cancer Research Network
FRIDA
Jewish General Hospital
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute